{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:45:31Z","timestamp":1780357531397,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T cells derived from gene-edited induced pluripotent stem cells (iPSCs) are a promising alternative cell source for universal T-cell immunotherapy. However, current preclinical evaluations of iPSC-derived T cells (iPSC-T cells) rely on immunodeficient mouse models, which limit the assessment of immune-related adverse events and in vivo immune cell interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To overcome these limitations, we developed a preclinical nonhuman primate model to evaluate the safety and cellular kinetics of iPSC-T cells. iPSCs were generated from peripheral blood T cells obtained from two rhesus macaques and redifferentiated in vitro into CD8\u03b1\u03b2\n                      <jats:sup>-<\/jats:sup>\n                      CD3\n                      <jats:sup>+<\/jats:sup>\n                      innate-like T cells. Phenotypic and functional characterization was performed using flow cytometric analyses. The proliferative capacity of iPSC-T cells was assessed by repeated stimulation with phytohemagglutinin (PHA), and cytotoxic function was evaluated through co-culture assays with target cells. The cells were further transduced with GFP using retroviral vectors during expansion. Autologous GFP\u207a iPSC-T cells were administered to the donor macaques in three separate infusions to assess in vivo safety and cellular kinetics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The iPSC-T cells exhibited both antigen-dependent and antigen-independent cytotoxicity and demonstrated robust proliferative capacity upon repeated stimulation. Stable GFP expression was maintained during cell expansion. Following autologous infusion, no safety concerns were observed for up to one year after the first administration. Cellular kinetic analyses revealed that the infused iPSC-T cells trafficked to the alveolar space and were no longer detectable in peripheral circulation by seven days post-infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings establish a unique immunocompetent primate model for assessing the safety and\n                      <jats:italic>in vivo<\/jats:italic>\n                      behavior of iPSC-T cells. This platform enables more physiologically relevant preclinical evaluation and supports the development of iPSC-derived T-cell immunotherapies for cancer and autoimmune diseases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1653275","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:48:40Z","timestamp":1769150920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Yasuyuki","family":"Miyake","sequence":"first","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Iriguchi","sequence":"additional","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kawana-Tachikawa","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Imai","sequence":"additional","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahoru","family":"Taya","sequence":"additional","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Latent Infection, National Institute of Infectious Diseases, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Miura","sequence":"additional","affiliation":[{"name":"Institute for Frontier Life and Medical Sciences, Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sakawaki","sequence":"additional","affiliation":[{"name":"Institute for Frontier Life and Medical Sciences, Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Matano","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases, Japan Institute for Health Security","place":["Tokyo, Japan"]},{"name":"Institute of Medical Science, University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFV by CAR-T cells enhances anti-tumor efficacy in vivo","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00176","article-title":"Induced pluripotent stem cells: Challenges and opportunities for cancer immunotherapy","volume":"5","author":"Sachamitr","year":"2014","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2399-1","article-title":"Cloning and expansion of antigen-specific T cells using iPS cell technology: development of \u201coff-the-shelf\u201d T cells for the use in allogeneic transfusion settings","volume":"107","author":"Kawamoto","year":"2018","journal-title":"Int J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2019.11.011","article-title":"iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity","volume":"14","author":"Suzuki","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.04.019","article-title":"Path to the clinic: Assessment of iPSC-based cell therapies in vivo in a nonhuman primate model","volume":"7","author":"Hong","year":"2014","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.008","article-title":"Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease","volume":"21","author":"Iwamoto","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2018.04.025","article-title":"Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response","volume":"10","author":"Ueda","year":"2018","journal-title":"Stem Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.12.007","article-title":"Tissue-resident memory T cells","volume":"41","author":"Schenkel","year":"2014","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2009.00554.x","article-title":"Reference values of clinical chemistry and hematology parameters in rhesus monkeys (Macaca mulatta)","volume":"16","author":"Chen","year":"2009","journal-title":"Xenotransplantation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell\u2013mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti\u2013CD20-CD28-CD3 \u03b6 Chimeric antigen receptor\u2013modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03053","article-title":"Functional MAIT cells are associated with reduced simian\u2013human immunodeficiency virus infection","volume":"10","author":"Murugesan","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24482","article-title":"Preferential migration of effector CD8+ T cells into the interstitium of the normal lung","volume":"115","author":"Galkina","year":"2005","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-022-00969-0","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat BioMed Eng"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.312","article-title":"Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys","volume":"20","author":"Tarantal","year":"2012","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1883657","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:22:00Z","timestamp":1779898920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1653275"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1653275","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1653275"}}